Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2013 |
| Start Date: | March 2008 |
A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase 2 Dose (Renal Cell Carcinoma and Non-Small Cell Lung Carcinoma)
The main purpose of this study is to:
- Evaluate the safety of vorinostat in combination with sorafenib.
- Determine the largest dose of vorinostat + sorafenib that can be given safely to
humans.
- Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in
decreasing their size.
- Study the side effects of vorinostat + sorafenib.
Eligibility criteria include but are not limited to:
- 18 years or older with advanced solid tumor(s),
- Renal cell or non-small cell lung cancer.
We found this trial at
1
site
13001 E. 17th Pl.
Aurora, Colorado 80045
Aurora, Colorado 80045
303-724-5000
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
Click here to add this to my saved trials
